In vivo pharmacology of butylthio[2.2.2](LY297802/NNC11-1053), and orally acting antinociceptive muscarinic agonist

Life Sciences

Volumn 60, Issue 13-14, 1997, Pages 969-976

  Shannon, Harlan E ^a   Womer, Daniel E ^a   Bymaster, Frank P ^a   Calligaro, David O ^a   DeLapp, Neil C ^a   Mitch, Charles H ^a   Ward, John S ^a   Whitesitt, Celia A ^a   Swedberg, Michael D B ^b   Sheardown, Malcolm J ^b   Fink Jensen, Anders ^b   Olesen, Preben H ^b   Rimvall, Karin ^b   Sauerberg, Per ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

antinociception; butylthio 2.2.2 ; M2 antagonist

Indexed keywords

3 (4 BUTYLTHIO 1,2,5 THIADIAZOL 3 YL)QUINUCLIDINE; 3 [4 BUTYLTHIO 1,2,5 THIADIAZOL 3 YL] 1 AZABICYCLO[2.2.2]OCTANE; ANALGESIC AGENT; ARECOLINE DERIVATIVE; MORPHINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER RECEPTOR; OXOTREMORINE M; PIRENZEPINE; QUINUCLIDINYL BENZILATE; RADIOLIGAND; RECEPTOR SUBTYPE; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; BLADDER; COMPETITIVE INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ANTAGONISM; GUINEA PIG; HEART ATRIUM; HOT PLATE TEST; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; RAT; RECEPTOR AFFINITY; SALIVATION; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST; TREMOR; VAS DEFERENS; WRITHING TEST;

ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; ANIMALS; GUINEA PIGS; MICE; MUSCARINIC AGONISTS; RABBITS; RATS; THIADIAZOLES;

EID: 0030984542     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00036-2     Document Type: Conference Paper

References (24)

1. G. CHEN, J. Pharmacol. Exp. Ther. 12473-76 (1958).
2. A. HERZ, Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmacol. 242 414-429 (1962).
3. L.S. HARRIS, W.L. DEWEY, J.F. HOWES, J.S. KENNEDY and PARS, H., J. Pharmacol. Exp. Ther. 169 17-22 (1969).
4. J. METYS, N. WAGNER, J. METYSOVA and A. HERZ, Int. J. Neuropharmacol. 8 413-425 (1969).
5. J.D. IRESON, Br. J. Pharmacol. 40 92-101 (1970).
6. M.D.B. SWEDBERG, J. Pharmacol. Exp. Ther. 269 1021-1028 (1994).
7. J.F. HOWES, L.S. HARRIS, W.L. DEWE, and C.A. VOYDA, J. Pharmacol. Exp. Ther. 169 23-28, 1969.
8. S. FLODMARK and T. WRAMNER, Acta Phsyiol. Scand. 9 88-96 (1945).
9. V. STONE, W. MOON and F.H. SHOW, Br. Med. J., Feb. 18 471-473 (1961).
10. J. PETERSON, T.E. GORDH, P. HARTVIG and L. WIKLUND, Acta Aneasthesiol. Scand. 30 283-288 (1986).
11. F. DÖRJE, A.I. LEVEY and M. BRANN, Mol. Pharmacol. 90 459-462 (1991).
12. P.J. BARNES, Thorax 44 161-167 (1989).
13. A.I. LEVEY, Life Sci. 52 441-448 (1993).
14. L. NORONHA-BLOB, V. LOWE, A. PATTON., B. CANNING, D. COSTELLO and W.J. KINNIER, J. Pharmacol. Exp. Then 249 843-851 (1989).
15. D.A. BROWN, S. FATHERAZI, J. GARTHWAITE and R.D. WHITE, Brit. J. Pharmacol. 70 577-592 (1980).
16. R.A. NORTH, B.E. BLACK and A.M. SUPRENANT, J. Physiol. 368 435-452 (1985).
17. P.O. GILLBERG and H. ASKMARK, J. Neural Transm. 85 31-39 (1991).
18. N.J. BUCKLEY, T.I. BONNER and MR. BRANN, J. Neurosci. 8 4646-4652 (1988).
19. A.I. LEVEY, C.A. KITT, W.F., SIMONDS, D.L. PRICE and M.R. BRANN, J. Neurosci. 11 3218-3226 (1991).
20. P.H. OLESEN, P. SAUERBERG, S. TREPPENDAHL, O. LARSSON, M.J. SHEARDOWN, P.D. SUZDAK, C.H. MITCH, J.S. WARD, F.P. BYMASTER, H.E. SHANNON and M.D.B. SWEDBERG. Eur. J. Med. Chem. 31 221-230 (1996).
21. J.H. JAFF and W.R. MARTIN, Goodman and Gilman's The Pharmacological Basis of Therapeutics, A. Goodman Gilman, T.W. Rall, A.S. NiIes and P. Taylor (eds), 485-521, Pergamon Press, New York (1990).
22. L. GHELARDINI, L. FANETTI, M. MALCANGIO, A., MALMBERG, O.P. AIELLO, A. GIOTTI and A. BARTOLINI, Eur. J. Pharmacol. 183 1941-1942 (1990).
23. E.T. IWAMOTO and L. MARION, J. Pharmacol. Exp, Ther. 266 329-339, 1993.
24. N.J. BUCKLEY, T.I. BONNER, C.M. BUCKLEY and M.R. BRANN, Mol. Pharmacol. 35 469-479 (1989).